Kalaris Therapeutics (NASDAQ:KLRS) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Kalaris Therapeutics (NASDAQ:KLRS) from a hold rating to a sell rating in a research report sent to investors on Saturday.

A number of other equities analysts have also commented on KLRS. Chardan Capital assumed coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Finally, Citizens Jmp started coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.00.

Kalaris Therapeutics Price Performance

NASDAQ:KLRS opened at $9.11 on Friday. The company has a market capitalization of $170.36 million, a P/E ratio of -2.42 and a beta of -0.09. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $12.90. The business has a fifty day simple moving average of $8.48 and a two-hundred day simple moving average of $5.79.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02.

Institutional Trading of Kalaris Therapeutics

Hedge funds have recently bought and sold shares of the company. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics during the third quarter valued at approximately $58,000. XTX Topco Ltd purchased a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at $65,000. Bridgeway Capital Management LLC bought a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at $130,000. Belpointe Asset Management LLC purchased a new position in Kalaris Therapeutics in the 3rd quarter worth $231,000. Finally, Fortis Capital Advisors LLC bought a new stake in Kalaris Therapeutics in the third quarter worth $231,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.